The effects of genomic germline variant reclassification on clinical cancer care
暂无分享,去创建一个
[1] Julie O. Culver,et al. Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry , 2018, Journal of the National Cancer Institute.
[2] S. Manley,et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.
[3] C. Vnencak-Jones,et al. The impact of variant classification on the clinical management of hereditary cancer syndromes , 2018, Genetics in Medicine.
[4] S. Macklin,et al. Observed frequency and challenges of variant reclassification in a hereditary cancer clinic , 2017, Genetics in Medicine.
[5] R. Jagsi,et al. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Chen,et al. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 , 2017, Clinical Cancer Research.
[7] Colin C Pritchard,et al. Family-Specific Variants and the Limits of Human Genetics. , 2016, Trends in molecular medicine.
[8] T. Slavin,et al. When Clinical Care Depends on the Answer: The Challenges of Assessing Germline Cancer Gene Variants. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Vijai Joseph,et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Mark E. Robson,et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations , 2016, Nature Reviews Clinical Oncology.
[11] J. Abraham,et al. Understanding of BRCA VUS genetic results by breast cancer specialists , 2015, BMC Cancer.
[12] T. Slavin,et al. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management , 2015, Front. Oncol..
[13] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[14] J. Powers,et al. Adverse Events in Cancer Genetic Testing: The Third Case Series , 2014, Cancer journal.
[15] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[16] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[17] W. Otten,et al. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life , 2008, Psycho-oncology.
[18] Joan Borràs,et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. , 2004, The Journal of urology.
[19] J. Weitzel,et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.
[20] A. González Martín. Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer? , 2017, The Lancet. Oncology.
[21] Antonio González Martín. Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer , 2017 .
[22] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .